Novel dendritic peptide bolaamphiphiles that are safe and efficient for siRNA delivery.
Lipid nanoparticles (LNPs) and polymeric vectors have great promise for therapeutic delivery of siRNA to tumors. Despite major advances in this area, these LNPs and vectors may cause cell membrane disruption thus altering cell behavior and causing cytotoxicity.
Researchers at the University of California, Irvine have developed novel dendritic peptide bolaamphiphiles that cause low cellular membrane damage and also these bolaamphiphiles exhibited 20-40 times higher cellular uptake than Lipofectamine. In addition, experiments showed that these bolaamphiphiles displayed robust luciferase knockdown in luciferase expressing cell lines with minimal cytotoxicity.
These bolaamphiphiles may be used as research reagents or as a drug delivery vehicle for siRNA delivery.
|United States Of America||Issued Patent||9,867,845||01/16/2018||2015-033|
School of Physical Sciences
University of California, Irvine